Prenosis
PrivateLast Round
Grant
Jan 29, 2026
Total Funding Raised
$55.85M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Prenosis operates in Healthcare & Life Sciences and is based in Chicago, Illinois. Its latest recorded funding round was a Grant round in January 2026.
Prenosis is a healthcare technology company that develops integrated diagnostics and therapeutics for critical care conditions using artificial intelligence.
Sector
Healthcare & Life Sciences
Verticals
Medical AI, Medical Devices, Precision Medicine, Healthcare Analytics
Business Model
B2B
Customer Profile
Subscription SaaS, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Prenosis Comparables
Compare Prenosis with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Bayesian Health | 90% | |
| Ambient Clinical Analytics | 88% | |
| Cirrus Dx, Inc. | 82% |
For institutional investors. Book with your work email.
Prenosis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jan 29, 2026 | ||||
| Series A | Jan 29, 2024 | ||||
| Grant | Jul 12, 2023 | ||||
| Grant | Jun 7, 2023 | ||||
| VC Round | Mar 9, 2022 | ||||
Grant | Nov 17, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Prenosis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UCI Health Ventures | Series A, Grant |
| Biomedical Advanced Research and Development Authority (BARDA) | Grant |
| NIH RADx | Grant |
| U.S. Department of Defense | Grant |
| National Institute of General Medical Sciences | Grant |
| Public Health Emergency Medical Countermeasures Enterprise | Grant |
| Global Health Investment Corporation | Series A, Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 29, 2026
$20M raised in grant funding.
- Dec 19, 2025
Received the inaugural UL Enterprise Safety Science Award for Sepsis ImmunoScore.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_awardAug 31, 2026
Prenosis is named a Chicago Innovation Award winner by Chicago Innovation and joins fellow 2025 winners in New York on Aug 31st '26 to ring the Nasdaq Opening Bell, recognizing its Sepsis ImmunoScore innovation.
For institutional investors. Book with your work email.
Prenosis Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Prenosis's valuation, stock price, and market status.
Is Prenosis a public or private company?
Prenosis is a private company.
What is the current stock price of Prenosis?
Prenosis is a private company, so its shares have no public market price. Caplight tracks Prenosis's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Prenosis worth (valuation)?
Valuation information for Prenosis is not publicly available.
Can I buy Prenosis stock?
Prenosis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Prenosis's last funding round?
Prenosis's most recent funding round was Grant on January 29, 2026.
Who are the main investors in Prenosis?
Key investors in Prenosis include PACE Healthcare Capital.
Will Prenosis IPO soon?
No public IPO plans have been announced for Prenosis.
How can I track Prenosis secondary market activity?
Caplight tracks bids, offers, and trades in Prenosis's shares on secondary markets.